RIGI and neoplasm: Collectively, we show that intratumoral injection of a synthetic RIG-I ligand led to the recruitment of activated immune cells into the tumor microenvironment and tumor-draining lymph nodes, which was unaltered by treatment with dabrafenib and trametinib.